Africa Injectable Drugs Market, by Molecule Type (Large Molecule and Small Molecule), by Route of Administration (Intravenous, Intramuscular, Sub-cutaneous, and Others, by End User (Hospitals, Specialty Clinics, and Others), and by Country/Region (South Africa, Central Africa, and North Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jun 2022

Code : CMI4949

Pages :175

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Africa Injectable Drugs Market: Restraint

The major factors that hinder the growth of Africa injectable drugs market include the lack of funding for manufacturing injectable products. Lack of finances can also be a significant challenge to manufacturing injectable pharmaceuticals.

Lack of funding for manufacturing injectable products

Companies covered:

Apotex Inc., Fresenius Kabi India Pvt. Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Gland Pharma Limited, hameln pharma gmbh, Merck & Co., Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and PANPHARMA S.A.

Growing manufacturing facilities for pharmaceutical drugs are expected to drive the market growth during the forecast period.

The ever-growing number of healthcare practitioners leads to a surge in the demand for injectable drugs. For instance, in Africa estimated there were about 266,279 doctors in 2020. Thus, key market players are engaged in enhancing their manufacturing capabilities and strengthening their position in the market, which will drive the market growth. For instance, in sub-Saharan Africa, only Kenya, Nigeria, and South Africa have a relatively considerable industry with a significant number of manufacturing companies. Moreover, initiatives by governments and market players to develop a local drug industry in sub-Saharan Africa is expected to create a significant opportunity for the market players.